Form 4: Pfizer CEO Albert Bourla Awarded Stock Appreciation Rights

Pfizer's CEO, Albert Bourla, was granted stock appreciation rights (SARs) that will be settled in shares of Pfizer common stock.

Summary

• On February 27, 2024, Albert Bourla, the Chairman and CEO of Pfizer Inc., was granted stock appreciation rights (SARs).
• These SARs are divided into two tranches: 644,640 SARs that will vest and be settled on February 27, 2029 (the fifth anniversary of the grant date), and 569,600 SARs that will vest and be settled on February 27, 2031 (the seventh anniversary of the grant date).
• The exercise price for both tranches of SARs is $26.89.
• The SARs will be settled in shares of Pfizer common stock upon vesting.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The granting of stock appreciation rights to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's stock value.

Future Outlook

The stock appreciation rights will vest in 5 and 7 years, incentivizing long-term performance.

Industry Context

Granting stock appreciation rights is a common practice in executive compensation to align management's interests with shareholder value.

Comparison to Industry Standards

• Stock appreciation rights are a common component of executive compensation packages in the pharmaceutical industry, similar to grants awarded to executives at companies like Johnson & Johnson and Merck.
• The vesting schedules of five and seven years are within the typical range for such awards, aligning with long-term strategic goals.

Stakeholder Impact

• Shareholders may view the granting of stock appreciation rights positively as it incentivizes the CEO to increase shareholder value.

Key Dates